Harrow Q1 revenue $47.8M (+38% YoY); VEVYE revenue $21.5M (+35% QoQ); reaffirms >$280M FY2025 guidance

HARROW, INC.

2025-Q1 EPS reported -$0.50 revenue$47,831,000

Revenues $47.8M, up 38% YoY; GAAP net loss $(17.8)M; adjusted EBITDA $(2.0)M.
VEVYE revenue $21.5M (+35% QoQ); VAFA launch drove new RXs >4X and prescribers >4X at PhilRx.
VEVYE new patent exp. 2042 added to Orange Book; second production site expected H1 2026.
TRIESENCE received CMS pass-through status Apr 1; accounts ordering more than doubled since Jan.
Refinancing $222.75M debt in active discussions; expect resolution by late summer/early fall.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.